Form 4: BridgeBio Director Sells $13.3M in Stock Under 10b5-1 Plan

BridgeBio Pharma Director Frank McCormick sold over 198,000 shares of common stock for approximately $13.3 million under a pre-arranged 10b5-1 trading plan.

Summary

• Frank McCormick, a Director of BridgeBio Pharma, Inc. (BBIO), reported the sale of common stock.
• The transactions occurred on October 29, 2025.
• A total of 198,359 shares of common stock were disposed of across multiple transactions.
• The sales were executed at weighted average prices ranging from $65.4764 to $69.2358 per share.
• The total value of shares sold is approximately $13,300,000.
• These sales were made pursuant to a Rule 10b5-1 sales plan adopted by Mr. McCormick on August 28, 2024.
• Following these transactions, Mr. McCormick beneficially owns 679,979 shares indirectly through the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 and 83,275 shares directly.

Sentiment

Score: 4

Explanation: Insider selling, even under a 10b5-1 plan, is generally viewed as a neutral to slightly negative signal, as it represents a reduction in insider ownership. However, the pre-planned nature mitigates the negative impact compared to unplanned sales.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned divestment rather than an immediate reaction to new, undisclosed information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by the market as a lack of confidence or a move to diversify holdings away from the company.

Future Outlook

NA

Management Comments

• "This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024."

Industry Context

Insider transactions are common across all industries, including biotechnology and pharmaceuticals. Sales under 10b5-1 plans are a standard practice for executives and directors to manage their equity holdings while avoiding accusations of trading on material non-public information.

Comparison to Industry Standards

• Sales under Rule 10b5-1 plans are a common and accepted practice for corporate insiders to diversify their portfolios and manage liquidity without violating insider trading laws.
• This is a standard mechanism used by executives and directors across publicly traded companies, including those in the biotech sector like Regeneron Pharmaceuticals or Vertex Pharmaceuticals, to execute pre-scheduled stock sales.
• The volume of shares sold represents a portion of the director's total holdings, which is typical for such plans.

Corporate Governance

Related Party Transactions

• The sale of common stock by Director Frank McCormick is a transaction involving a related party (an insider).

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a signal, though the 10b5-1 plan suggests it's a pre-planned financial management decision rather than a reaction to new company-specific news.

Key Dates

Recommendation

While insider selling can sometimes be a negative signal, these transactions were executed under a pre-arranged Rule 10b5-1 plan adopted over a year prior to the sales. This indicates a planned diversification or liquidity event rather than a reaction to recent negative company developments. Therefore, it does not provide a strong basis for a 'sell' recommendation, nor does it suggest a 'buy' opportunity. Investors should 'hold' and consider broader company fundamentals and market conditions.

Keywords

BridgeBio Pharma, BBIO, Frank McCormick, Director, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Transaction, Biotechnology, Pharmaceutical